340 related articles for article (PubMed ID: 22465268)
1. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
[TBL] [Abstract][Full Text] [Related]
2. Duration of antiresorptive effects of low-dose zoledronate in osteopenic postmenopausal women: a randomized, placebo-controlled trial.
Grey A; Bolland M; Mihov B; Wong S; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2014 Jan; 29(1):166-72. PubMed ID: 23761303
[TBL] [Abstract][Full Text] [Related]
3. Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.
Grey A; Bolland M; Wattie D; Horne A; Gamble G; Reid IR
J Bone Miner Res; 2010 Oct; 25(10):2251-5. PubMed ID: 20499349
[TBL] [Abstract][Full Text] [Related]
4. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
[TBL] [Abstract][Full Text] [Related]
5. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
[TBL] [Abstract][Full Text] [Related]
6. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
7. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.
Grey A; Bolland MJ; Wattie D; Horne A; Gamble G; Reid IR
J Clin Endocrinol Metab; 2009 Feb; 94(2):538-44. PubMed ID: 19050050
[TBL] [Abstract][Full Text] [Related]
8. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
9. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
[TBL] [Abstract][Full Text] [Related]
12. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
14. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
15. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
Bauer DC; Black DM; Garnero P; Hochberg M; Ott S; Orloff J; Thompson DE; Ewing SK; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia.
Gilfillan CP; Strauss BJ; Rodda CP; Bowden DK; Kean AM; Obaid M; Crawford BA
Calcif Tissue Int; 2006 Sep; 79(3):138-44. PubMed ID: 16969592
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS
J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357
[TBL] [Abstract][Full Text] [Related]
18. Correlation between salivary and serum markers of bone turnover in osteopenic rats.
Pellegrini GG; Gonzales CM; Somoza JC; Friedman SM; Zeni SN
J Periodontol; 2008 Jan; 79(1):158-65. PubMed ID: 18166106
[TBL] [Abstract][Full Text] [Related]
19. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
Langdahl B; Binkley N; Bone H; Gilchrist N; Resch H; Rodriguez Portales J; Denker A; Lombardi A; Le Bailly De Tilleghem C; Dasilva C; Rosenberg E; Leung A
J Bone Miner Res; 2012 Nov; 27(11):2251-8. PubMed ID: 22777865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
